PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12098845-7	2002	As the dose of insulin increased from 6 to 9 U/kg, the area under curve (AUC) of the enteric-coated capsules containing 50 mg sodium salicylate increased from 73.2 +/- 27.8% to 121.4 +/- 102.7% reduction, but the RH did not change significantly.	Sodium Salicylate	126-143	insulin	Canis lupus familiaris	15-22	
12098845-5	2002	Sodium salicylate, when used in insulin enteric-coated capsules (50 mg) mixed with insulin as a physical mixture, or prepared by wet granulation using 10% polyvinyl pyrollidone (PVP), or by freeze-drying, produced RH values ranging from 7.3 +/- 2.9% to 9.4 +/- 3.7%.	Sodium Salicylate	0-17	insulin	Canis lupus familiaris	32-39	
12098845-5	2002	Sodium salicylate, when used in insulin enteric-coated capsules (50 mg) mixed with insulin as a physical mixture, or prepared by wet granulation using 10% polyvinyl pyrollidone (PVP), or by freeze-drying, produced RH values ranging from 7.3 +/- 2.9% to 9.4 +/- 3.7%.	Sodium Salicylate	0-17	insulin	Canis lupus familiaris	83-90	
12098845-6	2002	When sodium salicylate (100 mg) was used with insulin in freeze-dried granules an RH value of 10 +/- 2.6% was produced.	Sodium Salicylate	5-22	insulin	Canis lupus familiaris	46-53	
11955805-0	2002	Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs.	Sodium Salicylate	65-82	insulin	Canis lupus familiaris	17-24	
11955805-2	2002	The capsules containing insulin formulated with sodium salicylate (50 mg) and prepared by either physical mixing or wet granulation using 10% polyvinyl pyrollidone gave almost the same results producing a maximum reduction in plasma glucose level (C(max)) of 81.53+/-8.21 and 79.59+/-5.75%, T(max) of 6 and 5 h, area under the curve (AUC) of 69.37+/-48.64 and 57.98+/-23.15% reduction hour (% red.	Sodium Salicylate	48-65	insulin	Canis lupus familiaris	24-31	
11955805-4	2002	Formulation of insulin with sodium salicylate in PEG 4000 produced a lower AUC of 37.30+/-10.36% red.	Sodium Salicylate	28-45	insulin	Canis lupus familiaris	15-22	
11955805-9	2002	In conclusion, 25-30% reduction in plasma glucose levels and RH of about 12.5% relative to subcutaneous injection of regular soluble insulin can be achieved by formulating insulin in Witepsol W35 (1 g) with sodium salicylate (50 mg) as an absorption promoter, reducing the resulting mass into particle size 180-315 microm, packing into hard gelatin capsules and coating with Eudragit S100.	Sodium Salicylate	207-224	insulin	Canis lupus familiaris	133-140	
11955805-9	2002	In conclusion, 25-30% reduction in plasma glucose levels and RH of about 12.5% relative to subcutaneous injection of regular soluble insulin can be achieved by formulating insulin in Witepsol W35 (1 g) with sodium salicylate (50 mg) as an absorption promoter, reducing the resulting mass into particle size 180-315 microm, packing into hard gelatin capsules and coating with Eudragit S100.	Sodium Salicylate	207-224	insulin	Canis lupus familiaris	172-179	
12064061-5	2002	Sodium salicylate, when used in insulin enteric coated capsules (50 mg) mixed with insulin as a physical mixture or prepared by wet granulation using 10% polyvinyl pyrollidone (PVP) or by freeze drying, produced RH values ranged from 7.3 +/- 2.9 to 9.4 +/- 3.7%.	Sodium Salicylate	0-17	insulin	Canis lupus familiaris	32-39	
12064061-5	2002	Sodium salicylate, when used in insulin enteric coated capsules (50 mg) mixed with insulin as a physical mixture or prepared by wet granulation using 10% polyvinyl pyrollidone (PVP) or by freeze drying, produced RH values ranged from 7.3 +/- 2.9 to 9.4 +/- 3.7%.	Sodium Salicylate	0-17	insulin	Canis lupus familiaris	83-90	
12064061-6	2002	When sodium salicylate (100 mg) was used with insulin in freeze-dried granules an RH value of 10 +/- 2.6% was produced.	Sodium Salicylate	5-22	insulin	Canis lupus familiaris	46-53	
12064061-7	2002	As the dose of insulin increased from 6 to 9 U/kg, the AUC of the enteric coated capsules containing 50 mg sodium salicylate increased from 73.2 +/- 27.8 to 121.4 +/- 102.7% reduction but the RH id not significantly change.	Sodium Salicylate	107-124	insulin	Canis lupus familiaris	15-22	
676763-0	1978	Effects of sodium salicylate on plasma insulin concentration and fatty acid turnover in dogs.	Sodium Salicylate	11-28	insulin	Canis lupus familiaris	39-46	
676763-1	1978	The effects of intravenous sodium salicylate administration on plasma concentrations of insulin, free fatty acids (FFA) and glucose were studied in intact, anaesthetized dogs both during basal and isoprenaline stimulated lipolysis.	Sodium Salicylate	27-44	insulin	Canis lupus familiaris	88-95	
676763-2	1978	In both situations sodium salicylate reduced the plasma concentrations of insulin.	Sodium Salicylate	19-36	insulin	Canis lupus familiaris	74-81	
676763-4	1978	The reduced plasma insulin concentrations effected by sodium salicylate is most likely secondary to the concomitant fall in plasma FFA concentrations due to inhibition of FFA mobilization from adipose tissue.	Sodium Salicylate	54-71	insulin	Canis lupus familiaris	19-26	
11725967-3	2001	Insulin suppositories containing sodium salicylate (50 mg) produced a maximum reduction of plasma glucose concentration (Cmax) of 55 +/- 11%, an area under the curve (AUC) of 252 +/- 59% reduction h; and a relative hypoglycemia (RH) of 49 +/- 12% relative to subcutaneous injection of insulin (4 U/kg).	Sodium Salicylate	33-50	insulin	Canis lupus familiaris	0-7	
11725967-3	2001	Insulin suppositories containing sodium salicylate (50 mg) produced a maximum reduction of plasma glucose concentration (Cmax) of 55 +/- 11%, an area under the curve (AUC) of 252 +/- 59% reduction h; and a relative hypoglycemia (RH) of 49 +/- 12% relative to subcutaneous injection of insulin (4 U/kg).	Sodium Salicylate	33-50	insulin	Canis lupus familiaris	285-292	
6132970-1	1983	Sodium salicylate and 5-methoxysalicylate both increased the rectal absorption of insulin in dogs when co-administered with insulin in various formulations.	Sodium Salicylate	0-17	insulin	Canis lupus familiaris	82-89	
6132970-1	1983	Sodium salicylate and 5-methoxysalicylate both increased the rectal absorption of insulin in dogs when co-administered with insulin in various formulations.	Sodium Salicylate	0-17	insulin	Canis lupus familiaris	124-131